Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Doug Mills/The New York Times/Pool/Getty Images

Trump administration advisers are hinting at a willingness to spend billions and elevate their risk tolerance in the hope of getting coronavirus treatments out this year.

What they're saying: "There had been frustration about how slow CDC was moving on a vaccine, and there had been discussions on how to bypass some of the bureaucracy and speed the process up significantly," a White House official told Axios' Alayna Treene.

The plan: The administration wants to organize public-private partnerships — with taxpayers assuming the risk — to produce vaccines on scale before widespread trials have ended. 

  • "Called 'Operation Warp Speed,' the program will pull together private pharmaceutical companies, government agencies and the military to try to cut the development time for a vaccine by as much as eight months," Bloomberg reports.
  • Reality check: This is billed as a way to get 100 million doses to the public by the end of this year and shorten the 12- to 18-month timeline laid out by the NIH's Anthony Fauci, but even that window was extremely optimistic.

The higher risk tolerance: The administration is reportedly preparing to give an emergency use authorization for Gilead's remdesivir, despite mixed results in early trials, the N.Y. Times reports.

  • Remdesivir appears to help people recover modestly quicker, which could be encouraging for those who get sick, but this drug is not any kind of a "cure" for this novel coronavirus, Axios' Bob Herman reports. Faster means 11 days vs. 15.
  • The data, which is still undergoing peer review and wasn't expected until May, shows an "important proof of concept" for remdesivir, but it isn't necessarily a "knockout," the NIH's Anthony Fauci said at the White House today.
  • Flashback: President Trump was promoting chloroquine and hydroxychloroquine as recently as two weeks ago.

The bottom line: There's a lot of pressure to get treatments and eventually a vaccine out to the public faster — but don't get your hopes up.

Go deeper

Surgeon general urges flu shots to prevent "double whammy" with coronavirus

Surgeon General Jerome Adams the American Red Cross National Headquarters on July 30. Photo: Jim Watson/AFP via Getty Images

U.S. Surgeon General Jerome Adams on Friday stressed the importance of Americans getting flu vaccines for the next influenza season, noting that the country has "been backsliding in terms of vaccine confidence over the last several years."

Why it matters: A bad flu season could put even more strain on the country's health system resources, which are especially limited in domestic coronavirus epicenters like Florida and California.

Updated Oct 7, 2020 - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

New Zealand now has active no coronavirus cases in the community after the final six people linked to the Auckland cluster recovered, the country's Health Ministry confirmed in an email Wednesday.

The big picture: The country's second outbreak won't officially be declared closed until there have been "no new cases for two incubation periods," the ministry said. Auckland will join the rest of NZ in enjoying no domestic restrictions from late Wednesday, Prime Minister Jacinda Ardern said, declaring that NZ had "beat the virus again."

Updated 8 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Health: Most COVID-19 survivors can weather risk of reinfection, study says — "Twindemic" averted as flu reports plummet amid coronavirus crisis
  2. Vaccine: FDA advisory panel endorses J&J COVID vaccine for emergency use — About 20% of U.S. adults have received first vaccine dose, White House says — New data reignites the debate over coronavirus vaccine strategy.
  3. Economy: What's really going on with the labor market.
  4. Local: All adult Minnesotans will likely be eligible for COVID-19 vaccine by summer — Another wealthy Florida community receives special access to COVID-19 vaccine.
  5. Sports: Poll weighs impact of athlete vaccination.